聚己内酯、聚（ε-己内酯-共聚-L-乳酸）和聚 L-乳酸作为鼠组织工程血管移植物支架密封聚合物的降解和评价。
Degradation and evaluation of polycaprolactone, poly(ε-caprolactone-co-L-lactide), and poly-L-lactic acid as scaffold sealant polymers for murine tissue-engineered vascular grafts.
机构信息
Center for Regenerative Medicine at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.
出版信息
Regen Med. 2019 Jul;14(7):627-637. doi: 10.2217/rme-2018-0069. Epub 2019 Jul 25.
Abstract
This study evaluates scaffold degradation and neotissue formation as a function of sealant polymer composition in tissue-engineered vascular grafts (TEVGs). Scaffolds fabricated from polyglycolic acid core and sealant composed of polycaprolactone (PCL), poly-L-lactic-acid (PLLA) or 50:50 copolymer poly(ε-caprolactone-co-L-lactide) (PCLA) were analyzed using accelerated degradation and scanning electron microscopy, and following implantation in a murine inferior vena cava interposition model. and characterization revealed statistically greater degradation of PCLA compared with both PCL and PLLA scaffolds, with similar neotissue formation across all groups. The wall thickness of PLLA TEVGs was statistically greater than PCL TEVGs at 2 weeks postimplant. Results of this study can be used to inform the rational design of future TEVGs.
摘要
本研究评估了支架降解和新组织形成作为组织工程血管移植物（TEVG）中密封聚合物组成的函数。 采用聚乙二醇酸芯和由聚己内酯（PCL）、聚 L-乳酸（PLLA）或 50:50 共聚物聚（ε-己内酯-co-L-乳酸）（PCLA）组成的密封剂制造的支架，通过加速降解和扫描电子显微镜进行分析，并在小鼠下腔静脉间置模型中进行植入后的分析。 结果表明，与 PCL 和 PLLA 支架相比，PCLA 支架的降解程度明显更大，而所有组的新组织形成情况相似。植入后 2 周时，PLLA TEVG 的壁厚明显大于 PCL TEVG。 本研究的结果可用于为未来的 TEVG 的合理设计提供信息。
相似文献
1
Degradation and evaluation of polycaprolactone, poly(ε-caprolactone-co-L-lactide), and poly-L-lactic acid as scaffold sealant polymers for murine tissue-engineered vascular grafts.
Regen Med. 2019 Jul;14(7):627-637. doi: 10.2217/rme-2018-0069. Epub 2019 Jul 25.
2
Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modeling.
Acta Biomater. 2019 Aug;94:183-194. doi: 10.1016/j.actbio.2019.05.063. Epub 2019 Jun 12.
3
Electrophoretic Deposition of Dexamethasone-Loaded Mesoporous Silica Nanoparticles onto Poly(L-Lactic Acid)/Poly(ε-Caprolactone) Composite Scaffold for Bone Tissue Engineering.
ACS Appl Mater Interfaces. 2016 Feb 17;8(6):4137-48. doi: 10.1021/acsami.5b11879. Epub 2016 Feb 5.
4
Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model.
PLoS One. 2016 Jul 28;11(7):e0158555. doi: 10.1371/journal.pone.0158555. eCollection 2016.
5
Heparinized PLLA/PLCL nanofibrous scaffold for potential engineering of small-diameter blood vessel: tunable elasticity and anticoagulation property.
J Biomed Mater Res A. 2015 May;103(5):1784-97. doi: 10.1002/jbm.a.35315. Epub 2014 Sep 16.
6
Fabrication of small-diameter in situ tissue engineered vascular grafts with core/shell fibrous structure and a one-year evaluation via rat abdominal vessel replacement model.
Biomater Adv. 2024 Dec;165:214018. doi: 10.1016/j.bioadv.2024.214018. Epub 2024 Aug 31.
7
Biomineral coating increases bone formation by ex vivo BMP-7 gene therapy in rapid prototyped poly(L-lactic acid) (PLLA) and poly(ε-caprolactone) (PCL) porous scaffolds.
Adv Healthc Mater. 2015 Mar 11;4(4):621-32. doi: 10.1002/adhm.201400424. Epub 2014 Dec 16.
8
A new tissue-engineered biodegradable surgical patch for high-pressure systems †.
Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):768-76. doi: 10.1093/icvts/ivv017. Epub 2015 Feb 26.
9
Evaluation of the use of an induced puripotent stem cell sheet for the construction of tissue-engineered vascular grafts.
J Thorac Cardiovasc Surg. 2012 Mar;143(3):696-703. doi: 10.1016/j.jtcvs.2011.06.046. Epub 2012 Jan 12.
10
Development and in vivo evaluation of small-diameter vascular grafts engineered by outgrowth endothelial cells and electrospun chitosan/poly(ε-caprolactone) nanofibrous scaffolds.
Tissue Eng Part A. 2014 Jan;20(1-2):79-91. doi: 10.1089/ten.TEA.2013.0020. Epub 2013 Nov 7.
引用本文的文献
1
Synergistic effect of Hypoxic Conditioning and Cell-Tethering Colloidal Gels enhanced Productivity of MSC Paracrine Factors and Accelerated Vessel Regeneration.
Adv Mater. 2025 Jan;37(3):e2408488. doi: 10.1002/adma.202408488. Epub 2024 Oct 9.
2
A novel degradable PCL/PLLA strapping band for internal fixation of fracture.
J Mater Sci Mater Med. 2023 Nov 8;34(11):57. doi: 10.1007/s10856-023-06759-7.
3
Influence of Single-Wall Carbon Nanotube Suspension on the Mechanical Properties of Polymeric Films and Electrospun Scaffolds.
Int J Mol Sci. 2023 Jul 4;24(13):11092. doi: 10.3390/ijms241311092.
4
Progress in the application of patch materials in cardiovascular surgery.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Feb 28;48(2):285-293. doi: 10.11817/j.issn.1672-7347.2023.220560.
5
Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth.
Commun Med (Lond). 2022 Jan 10;2:3. doi: 10.1038/s43856-021-00063-7. eCollection 2022.
6
Assessing the 3D Printability of an Elastomeric Poly(caprolactone--lactide) Copolymer as a Potential Material for 3D Printing Tracheal Scaffolds.
ACS Omega. 2022 Feb 20;7(8):7002-7011. doi: 10.1021/acsomega.1c06679. eCollection 2022 Mar 1.
7
Multiscale-Engineered Muscle Constructs: PEG Hydrogel Micro-Patterning on an Electrospun PCL Mat Functionalized with Gold Nanoparticles.
Int J Mol Sci. 2021 Dec 27;23(1):260. doi: 10.3390/ijms23010260.
8
Hemodynamic performance of tissue-engineered vascular grafts in Fontan patients.
NPJ Regen Med. 2021 Jul 22;6(1):38. doi: 10.1038/s41536-021-00148-w.
9
Epithelial Growth Factor-Anchored on Polycaprolactone/6-deoxy-6-amino--cyclodextrin Nanofibers: In Vitro and In Vivo Evaluation.
Polymers (Basel). 2021 Apr 16;13(8):1303. doi: 10.3390/polym13081303.
10
Sex and Tamoxifen confound murine experimental studies in cardiovascular tissue engineering.
Sci Rep. 2021 Apr 13;11(1):8037. doi: 10.1038/s41598-021-87006-3.
本文引用的文献
1
Synthesis, characterization and drug loading property of Monomethoxy-Poly(ethylene glycol)-Poly(ε-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) copolymers.
Sci Rep. 2016 Sep 28;6:34069. doi: 10.1038/srep34069.
2
Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model.
PLoS One. 2016 Jul 28;11(7):e0158555. doi: 10.1371/journal.pone.0158555. eCollection 2016.
3
TGF-β receptor 1 inhibition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte activation.
FASEB J. 2016 Jul;30(7):2627-36. doi: 10.1096/fj.201500179R. Epub 2016 Apr 8.
4
Long-Term Functional Efficacy of a Novel Electrospun Poly(Glycerol Sebacate)-Based Arterial Graft in Mice.
Ann Biomed Eng. 2016 Aug;44(8):2402-2416. doi: 10.1007/s10439-015-1545-7. Epub 2016 Jan 21.
5
Cardiovascular Tissue Engineering: Preclinical Validation to Bedside Application.
Physiology (Bethesda). 2016 Jan;31(1):7-15. doi: 10.1152/physiol.00018.2015.
6
The Tissue-Engineered Vascular Graft-Past, Present, and Future.
Tissue Eng Part B Rev. 2016 Feb;22(1):68-100. doi: 10.1089/ten.teb.2015.0100. Epub 2015 Oct 8.
7
The innate immune system contributes to tissue-engineered vascular graft performance.
FASEB J. 2015 Jun;29(6):2431-8. doi: 10.1096/fj.14-268334. Epub 2015 Feb 20.
8
A hypothesis-driven parametric study of effects of polymeric scaffold properties on tissue engineered neovessel formation.
Acta Biomater. 2015 Jan;11:283-94. doi: 10.1016/j.actbio.2014.09.046. Epub 2014 Oct 5.
9
Characterization of evolving biomechanical properties of tissue engineered vascular grafts in the arterial circulation.
J Biomech. 2014 Jun 27;47(9):2070-9. doi: 10.1016/j.jbiomech.2014.03.011. Epub 2014 Mar 15.
10
Computational model of the in vivo development of a tissue engineered vein from an implanted polymeric construct.
J Biomech. 2014 Jun 27;47(9):2080-7. doi: 10.1016/j.jbiomech.2013.10.009. Epub 2013 Oct 21.
Zotero 插件